Clinical trial
Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine…
NCT00421369 · Hadassah Medical Organization, Other · Completed
Key facts
| NCT number | NCT00421369 |
|---|---|
| Title | Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. |
| Official title | Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response. |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | sertraline, triiodothyronine (T3), reboxetine |
| Enrollment | 35 |
| Start date | Sep 1, 2007 |
| Completion | Aug 1, 2011 |
| First posted | Jan 12, 2007 |
| Last update posted | Mar 22, 2013 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: